EUVIMEDScopri EUVIMED
Crossref

Sorafenib: advances in targeted therapy for renal cell carcinoma

Robert E Hawkins, Fiona C Thistlethwaite

Future Prescriber · 2006

DOI: 10.1002/fps.12 ↗

At a glance

Journal article in Future Prescriber, 2006. Written by Robert E Hawkins and 1 co-authors.

AbstractDati bibliograficiCiteRelated studies

Abstract (original language)

Sorafenib is the first dual action oral multi‐kinase inhibitor to target serine/threonine and receptor tyrosine kinases in both the tumour cell and the tumour vasculature. Phase II studies and now the largest ever phase III study in advanced renal cell cancer suggest that sorafenib will be a valuable new therapy for patients with kidney cancer. Copyright © 2006 John Wiley & Sons, Ltd.

Cite

APA

Hawkins, R. E., & Thistlethwaite, F. C. (2006). Sorafenib: advances in targeted therapy for renal cell carcinoma. Future Prescriber. https://doi.org/10.1002/fps.12

Vancouver

Hawkins RE, Thistlethwaite FC. Sorafenib: advances in targeted therapy for renal cell carcinoma. Future Prescriber. 2006. doi:10.1002/fps.12

BibTeX
@article{Hawkins2006,
  author = {Hawkins, Robert E and Thistlethwaite, Fiona C},
  title = {Sorafenib: advances in targeted therapy for renal cell carcinoma},
  journal = {Future Prescriber},
  year = {2006},
  doi = {10.1002/fps.12}
}
Start for free →